Skip to content

Vertex Pharmaceuticals

US · VRTX #155 by market cap Listed 1970
515.02 -5.64 -1.08%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Official SEC filings

Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-21 19:43 UTC.

FormFiledOriginal document
10-Q2026-11-03Read on SEC.gov
8-K2026-11-02Read on SEC.gov
8-K2026-10-20Read on SEC.gov
8-K2026-09-01Read on SEC.gov
10-Q2026-08-04Read on SEC.gov
8-K2026-08-03Read on SEC.gov
8-K2026-07-07Read on SEC.gov
8-K2026-05-13Read on SEC.gov

SEC annual financial snapshot

Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-21 14:51 UTC.

MetricUSDBasisPeriod endFiledSource
Revenue$12.00BAnnual2025-12-312026-02-1310-K
Net income$3.95BAnnual2025-12-312026-02-1310-K
Operating cash flow$3.63BAnnual2025-12-312026-02-1310-K
Total assets$25.64BAs of2025-12-312026-02-1310-K
Total liabilities$6.98BAs of2025-12-312026-02-1310-K
Stockholders’ equity$18.67BAs of2025-12-312026-02-1310-K
Cash and cash equivalents$5.08BAs of2025-12-312026-02-1310-K

✦ Quant Financial Health how this is computed

Good
  • Altman Z-Score is 13.37, above the 3.0 "safe zone" threshold.
  • Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

✦ Quant Revenue Concentration how this is computed

Single-engine
  • TRIKAFTA/KAFTRIO is the largest reported line at 70.82% of revenue, across 6 reported segments.
  • The next-largest line, ALYFTREK, is a distant second at 20.51% - a sharp slowdown here would have little to offset it.

Revenue annual, last 8 years

Latest year +8.90% YoY

Margins

Gross margin
86.24%
Operating margin
37.95%
Net margin
32.94%

Key ratios & quality

PEG uses trailing P/E against the 3-year net income growth rate (5.97%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Revenue 3.05B4.16B6.21B7.57B8.93B9.87B11.02B12.00B
Gross profit 2.64B3.62B5.47B6.67B7.85B8.61B9.49B10.35B
Selling & admin expenses 557.62M658.50M770.50M840.10M944.70M1.14B1.46B1.75B
Research & development 1.42B1.75B1.83B3.05B2.66B3.69B8.26B4.04B
Operating profit 663.97M1.20B2.87B2.78B4.25B3.78B-233.40M4.55B
Pretax profit 600.24M1.39B3.12B2.73B4.23B4.38B248.50M4.64B
Tax -1.49B218.10M405.20M388.30M910.40M760.20M784.10M690.00M
Net profit 2.09B1.18B2.71B2.34B3.32B3.62B-535.60M3.95B
Basic EPS 851091314-215
Diluted EPS 8.094.5110.299.0112.8213.89-2.0815.32

Balance sheet

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Total current assets 3.84B4.82B8.13B9.56B13.23B14.14B9.60B11.20B
Cash & ST investments 3.17B3.81B6.66B7.52B10.78B11.22B6.12B6.61B
Inventory 124.36M167.50M280.80M353.10M460.60M738.80M1.21B1.69B
Total assets 6.25B8.32B11.75B13.43B18.15B22.73B22.53B25.64B
Total current liabilities 1.12B1.33B1.88B2.14B2.74B3.55B3.56B3.86B
Short-term debt 5.27M38.79M42.40M80.20M89.40M83.70M87.10M77.30M
Long-term debt ----------------
Total liabilities 1,810,695,000.002,233,221,000.003,065,000,000.003,332,500,000.004,238,200,000.005,149,800,000.006,123,600,000.006,977,200,000.00
Total equity 4.44B6.09B8.69B10.10B13.91B17.58B16.41B18.67B
Retained earnings -2.99B-1.85B858.70M3.20B6.52B10.14B9.61B13.56B

Cash flow

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Operating cash flow 1.27B1.57B3.25B2.64B4.13B3.54B-492.60M3.63B
Depreciation & amortization 72.42M106.90M109.50M125.60M148.30M181.30M207.20M209.80M
Free cash flow 1.17B1.49B2.99B2.41B3.93B3.28B-978.00M3.19B
Dividends paid ----------------
Stock buybacks / issuance -350.04M-192.00M-739.40M-1.56B-172.00M-653.70M-1.58B-2.39B
Ending cash balance 2.66B3.12B5.99B6.80B10.51B10.37B4.57B5.09B

Returns & efficiency

Line item 2018 2019 2020 2021 2022 2023 2024 2025
ROE % 64.8722.3736.7124.9327.6722.99-3.1522.54
ROA % 42.8216.1627.0218.6021.0417.71-2.3716.41
ROIC % 55.3819.9333.5423.1525.1618.96-5.2418.26
5-year avg ROE % -9.057.5725.9633.0835.3126.9321.8319.00
EBIT margin % 20.8234.9151.1636.8648.0144.832.5338.80
FCF / sales % 38.5535.8948.2431.8043.9533.22--26.61
Current ratio 3.433.614.334.464.833.992.692.90
Quick ratio 3.193.334.024.044.463.602.172.24
Debt / assets 9.407.957.937.204.963.567.747.92
LT debt / equity 13.1110.2410.248.785.824.1210.1010.46
Interest coverage 18.5924.8454.6045.4078.23100.329.12350.11
Revenue CAGR (3Y) % 43.4534.7335.6035.4628.9716.7313.3110.35
Net income CAGR (3Y) % ----117.523.7641.3310.10--5.97
FCF CAGR (3Y) % --102.6472.2727.0337.993.08---6.64

Revenue breakdown most recent period

Business

TRIKAFTA/KAFTRIO70.82%
ALYFTREK20.51%
Other product revenues3.79%
CASGEVY2.88%
JOURNAVX1.69%
PALSONIFY0.29%

Quote time 2026-11-20 20:02:21 · For reference only, not investment advice and not tailored to your situation.

Vertex Pharmaceuticals discussion 0 comments

Add a comment